GeneMedicine

About GeneMedicine

GeneMedicine Co., Ltd. is a biotechnology firm established in November 2014, specializing in the development of gene therapeutics. The company was founded by Dr. Chae-Ok Yun, who also serves as the CEO and CTO. Dr. Yun has an extensive background in the field, with 25 years dedicated to developing oncolytic virus and gene therapeutics, a journey that includes a Ph.D. in molecular biology from the Illinois Institute of Technology and postdoctoral research at Harvard Medical School. She is also a professor in the Department of Bioengineering at Hanyang University and a member of The National Academy of Engineering of Korea.

The company focuses on creating oncolytic adenovirus platform technologies to provide therapeutic solutions for intractable diseases, particularly cancer. GeneMedicine's business model is centered on its pipeline of genetically engineered oncolytic viruses designed to address limitations of existing cancer treatments. A key part of their strategy involves targeting immunologically 'cold' tumors that do not respond well to standard immunotherapies like CAR-T cells or immune checkpoint inhibitors. Revenue is generated through the development of its therapeutic pipeline and by offering Contract Development and Manufacturing Organization (CDMO) services to other gene and cell therapy companies. The company has constructed a state-of-the-art GMP manufacturing facility to support both its internal pipeline production and its CDMO business.

GeneMedicine's product pipeline includes several candidates, such as GM101, which has completed Phase I clinical trials for triple-negative breast cancer, and GM104, developed for the cancer immunotherapy market. The company has also developed a systemic delivery platform technology applicable to various virus types and cancer targets. Another area of development is the 'brain disease treatment platform,' a drug delivery system (DDS) that facilitates the delivery of therapeutic agents directly to the brain via intranasal administration. The company has successfully raised significant capital, including a Series A funding of $13.2 million in 2019 and a Series B of $27.2 million in 2021, to advance its clinical trials and expand its manufacturing capabilities.